Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc has demonstrated promising preliminary anti-tumor activity, particularly with its 3.0 mCi dose showing significantly improved progression-free survival (PFS) outcomes in heavily pre-treated patients compared to expected PFS rates in similar settings. The company's lead asset, VMT-α-NET, has achieved a noteworthy 71% complete response rate in combination therapy, indicating strong efficacy that outperforms other dual immunotherapy treatments. Furthermore, the ongoing trials support the potential for substantial market opportunities, particularly in neuroendocrine tumors (NETs), which represent a multi-billion dollar segment, positioning the company favorably for future financial growth.

Bears say

Perspective Therapeutics Inc faces a negative outlook due to significant challenges in cancer treatment efficacy, as evidenced by poor survival rates for metastatic patients, where the 1-year survival rate stands at approximately 50% and the 5-year rate ranges from 29-35%. The company's development of therapies utilizing the alpha-emitting isotope Lead-212 (212Pb) carries inherent risks, including the potential for clinical failures, delayed regulatory approvals, and adverse outcomes stemming from high toxicity levels associated with its treatments. Additionally, the competitive landscape in radiopharmaceuticals may heighten pressure on the firm, further complicating its ability to successfully advance its pipeline and maintain investor confidence.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.